The clinical investigation underway at Emory Healthcare allows hearts to be donated from patients who experience circulatory death (DCD). A circulatory death is when the heart has stopped beating and cannot be restarted. Circulation and oxygenation to the tissues stop as well. Emory was among the first five centers in the country to participate in this study.
This research is possible because of a new technology — TransMedic’s Organ Care System (OCS). The OCS is used to resuscitate and preserve hearts, giving doctors the ability to restart the heart and examine its viability for transplant. It’s estimated that this new approach can lead to a 30% increase in organs available for transplantation.
OCS is used in other types of organ donation and transplantation, but the study represents the first time it’s been used for heart transplantation.
“This is the forefront of heart transplantation,” says
Mani Daneshmand, MD, director of the Emory Heart & Lung Transplantation, Mechanical Circulatory Support, and Emory ECMO (Extracorporeal Membrane Oxygenation) Programs. Daneshmand is also the study’s Primary Investigator.
“We’re excited to be part of this trial; we’re performing transplants for patients who otherwise may have been waiting much longer for suitable organs,” he continues.
For end-stage heart failure patients, it’s hope for a new life. One patient at Emory experienced this hope firsthand.